NSE: POLYMED | BSE: 531768

Expensive Underperformer

Download real time

1230.10 -72.50 (-5.57%)

New 52W Low in past week

205.9K NSE+BSE Volume

NSE 27 Mar, 2026 3:31 PM (IST)

12,468.2

Market Cap

Market Leader

Beta 1Year

Low volatility

Poly Medicure Ltd. share price target and research reports

Name: Latest research reports of Poly Medicure Ltd. authored by FundsIndia and published by - Trendlyne research reports.
Item: Poly Medicure Ltd.
Rating: 5
Author: FundsIndia

Latest analyst research reports with target prices and PDF download for POLYMED, BSE:531768 Poly Medicure Ltd.

Search Inside the pdf :

Poly Medicure Ltd.

27 Dec 2024

1230.10

-5.57%

POLY MEDICURE LIMITED

Buy: Poly Medicure Ltd.

FundsIndia

Poly Medicure Ltd.'s price crossed below 30Day SMA today

Poly Medicure Ltd.

25 Jul 2024

1230.10

-5.57%

Fresh capacity and exports to drive momentum

Hold: Poly Medicure Ltd.

Target

ICICI Securities Limited

Poly Medicure’s (PolyMed) Q1FY25 performance was boosted by exports (~23% YoY) while domestic business growth (~12% YoY) took a pause on high base. The company has commissioned four new plants that may double its device manufacturing capacity to 1.8bn units p.a by FY25 end.

Poly Medicure has lost -37.22% in the last 6 Months

Poly Medicure Ltd.

09 Aug 2023

1230.10

-5.57%

Strong all-round performance

Hold: Poly Medicure Ltd.

Target

ICICI Securities Limited

Poly Medicure reported its all-time high revenues and EBITDA in Q1FY24 driven by solid performance across India (30% YoY growth) and Europe (35%). Softening of raw material prices fuelled a 220bps jump in gross margin. Ahead EBITDA margin is likely to be between 25-27%. Company will commercialise 4 manufacturing facilities in FY24 and launch 10-12 products in critical care segment, which will also likely drive growth and aid margin expansion.

Poly Medicure Ltd.'s price crossed below 30Day SMA today

Poly Medicure Ltd.

30 Jan 2023

1230.10

-5.57%

Growth sustains; margin expands

Accumulate: Poly Medicure Ltd.

Target

ICICI Securities Limited

Poly Medicure’s (Polymed) Q3FY23 performance beats our estimates on all fronts. Revenue grew 23.7% YoY to Rs2.8bn (I-Sec: Rs2.7bn) led by strong demand across segments. EBITDA margin improved 270bps YoY and 140bps QoQ to 24.9%, supported by strong gross margin expansion.

Poly Medicure Ltd. is trading below all available SMAs

Poly Medicure Ltd.

08 Nov 2022

1230.10

-5.57%

Strong print

Hold: Poly Medicure Ltd.

Recommendation Target

ICICI Securities Limited

Poly Medicure’s (Polymed) Q2FY23 performance beats our estimates on all fronts.
Revenue grew 23.0% YoY to Rs2.7bn (I-Sec: Rs2.6bn) led by strong demand across segments.